The Latest Cardiac and Vascular News
The THUNDERBOLT TM Computer Assisted Vacuum Thrombectomy (CAVTTM) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal ALAMEDA, Calif., June 15, 2026 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s…
THUNDERBOLT is the first CAVT platform to deliver modulated aspiration for acute ischemic stroke — enabling faster, more complete clot removal ALAMEDA, Calif., June 11, 2026 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced it has received U.S….
ALAMEDA, Calif., April 13, 2026 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT), which found that patients with acute intermediate-high risk pulmonary embolism (PE) who were treated with computer assisted vacuum thrombectomy (CAVT™) plus anticoagulation achieved greater functional improvement, including walking significantly further and […]
Acquisition to expand Boston Scientific’s cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies Conference call at 8:00 a.m. ET to discuss details of the transaction MARLBOROUGH, Mass. and ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc., […]
–The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to those who received only anticoagulation –Results of STORM-PE demonstrating superior efficacy of […]
ALAMEDA, Calif. – Oct. 27, 2025 – Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy (CAVT™), with anticoagulation achieved superior reduction in right heart strain compared to anticoagulation therapy alone in […]
ALAMEDA, Calif., Oct. 8, 2025 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) today announced that it will host an investor event on Sunday, October 26, 2025 from 4:00-5:00 PM Pacific Time / 7:00-8:00 PM Eastern Time at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) Conference….
Penumbra recently announced that Lightning Bolt® 6X with TraX,™ designed to reach and confidently remove thrombus below the knee, is now available in a 150 cm catheter length. This longer option brings the power and efficiency of Penumbra’s Computer Assisted Vacuum Thrombectomy (CAVT™) to the distal arteries in the body. “Lightning Bolt […]
Penumbra Inc., the world’s leading thrombectomy company, has secured CE Mark for its SwiftPAC™ neuro embolisation coil, which is part of the Swift™ Coil System and is now commercially available in Europe. Penumbra’s SwiftPAC coils are designed as a soft space-seeking “liquid metal” that conforms to the target vessel for dense […]
ALAMEDA, Calif., June 5, 2025 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi. The Ruby XL System is designed to help physicians achieve more…
